Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography

Pancreas

Volumn 40, Issue 4, 2011, Pages 533-539

  Jowell, Paul S ^a   Branch, Malcolm S ^a   Fein, Seymour H ^b   Purich, Edward D ^b   Kilaru, Rakhi ^c   Robuck, Gail ^d   D'Almada, Philip ^c   Baillie, John ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ChiRhoClin Inc   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d Ockham Development Group   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

biliary sphincterotomy; cannulation; pancreatic duct; Post ERCP pancreatitis; secretin prophylaxis

Indexed keywords

HORMONE DERIVATIVE; PLACEBO; SECRETIN;

ADULT; ARTICLE; BILIARY TRACT SURGERY; CANNULATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; POST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; VATER PAPILLOTOMY;

ADULT; AGED; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATITIS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SECRETIN; TREATMENT OUTCOME;

EID: 79955063400     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182152eb6     Document Type: Article

References (59)

1. Artifon ELA, Chu A, Freeman M, et al. A comparison of the consensus and clinical definitions of pancreatitis with a proposal to redefine post - endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2010; 39(4):530-535.
2. Testoni PA. Why the incidence of post-ERCP pancreatitis varies considerably? Factors affecting the diagnosis and the incidence of this complication. JOP. 2002; 3:195-201. (Pubitemid 38963809)
3. Freeman ML. Adverse outcomes of endoscopic retrograde cholangiopancreatography. Rev Gastroenterol Disord. 2002; 2:147-168. (Pubitemid 35469663)
4. Freeman ML. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP. 2002; 3:169-176. (Pubitemid 38963806)
5. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54:425-434. (Pubitemid 33661145)
6. Freeman ML, Guda NM, Freeman ML, et al. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004; 59:845-864. (Pubitemid 38879313)
7. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002; 56:488-495.
8. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001; 96:417-423.
9. Rabenstein T, Schneider HT, Bulling D, et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy. 2000; 32:10-19. (Pubitemid 30071900)
10. Sherman S, Ruffolo TA, Hawes RH, et al. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology. 1991; 101:1068-1075.
11. Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2004; 2:713-718. (Pubitemid 39013432)
12. Christoforidis E, Goulimaris I, Kanellos I, et al. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy. 2002; 34:286-292. (Pubitemid 34279516)
13. Testoni PA. Preventing post-ERCP pancreatitis: where are we? JOP. 2003; 4:22-32. (Pubitemid 38963797)
14. Badalov N, Tenner S, Baillie J. The prevention, recognition and treatment of post-ERCP pancreatitis. JOP. 2009; 10(2):88-97.
15. Cotton P, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009; 70(1):80-88.
16. Cooper ST, Slivka A. Incidence, risk factors, and prevention of post-ERCP pancreatitis. Gastroenterol Clin North Am. 2007; 36(2): 259-276. (Pubitemid 46803189)
17. Foster E, Leung J. Pharmacotherapy for the prevention of post-ERCP pancreatitis. Am J Gastroenterol. 2007; 102(1):52-55. (Pubitemid 46072043)
18. Sherman S, Cheng CL, Costamagna G, et al. Efficacy of recombinant human interleukin-10 in prevention of postYendoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009; 38(3):267-274.
19. Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post - endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas. 2008; 37(4):366-370.
20. Zheng M, Chen Y, Bai J, et al. Meta-analysis of prophylactic allopurinol use in post - endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2008; 37(3):247-253.
21. Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc. 2005; 62(2):245-250. (Pubitemid 41021551)
22. Zheng M, Bai J, Yuan B, et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol. 2008; 8:6.
23. Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007; 66(6):1126-1132. (Pubitemid 350179792)
24. Wagh MS, Sherman S. Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail. Am J Gastroenterol. 2007; 102(5):984-986. (Pubitemid 46698238)
25. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized prospective, multicenter study. Gastrointest Endosc. 2003; 58(1):23-29. (Pubitemid 38208742)
26. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc. 2002; 56(2):202-208.
27. Freeman ML. Pancreatic stents for prevention of post-ERCP pancreatitis: for everyday practice or for experts only? Gastrointest Endosc. 2010; 71(6):940-944.
28. Bailey AA, Bourke MJ, Williams SJ, et al. A prospective randomized trial of cannulation technique in ERCP: effects on technical success and post-ERCP pancreatitis. Endoscopy. 2008; 40(4):296-301. (Pubitemid 351524377)
29. Saad AM, Fogel EL, McHenry L, et al. Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc. 2008; 67(2):255-261.
30. Mundorf JB, Jowell PS, Branch MS, et al. Reduced incidence of post-ERCP pancreatitis in non-pancreas divisum patients who receive intravenous secretin during ERCP. Am J Gastroenterol. 1995; 90:1611.
31. Jowell PS, Robuck-Mangum G, Mergener K, et al. A double-blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin. Aliment Pharmacol Ther. 2000; 14:1679-1684. (Pubitemid 32011741)
32. Noble MD, Romac J, Vigna SR, et al. A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis. Gut. 2008; 57:1566-1571.
33. Masci E, Mariani A, Curioni S, et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003; 35:830-834. (Pubitemid 37254216)
34. Mehta SN, Pavone E, Barkun JS, et al. Predictors of post-ERCP complications in patients with suspected choledocholithiasis. Endoscopy. 1998; 30:457-463. (Pubitemid 28353554)
35. Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy. 2002; 34:280-285. (Pubitemid 34279515)
36. Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc. 2002; 56:652-656. (Pubitemid 36531698)
37. Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1995; 42:312-316.
38. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc. 2003; 57:291-294. (Pubitemid 36350781)
39. Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc. 2001; 54:209-213.
40. Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy - induced pancreatitis in high-risk patients. Gastrointest Endosc. 1993; 39:652-657. (Pubitemid 23282518)
41. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med. 1996; 335:919-923. (Pubitemid 26314444)
42. Andriulli A, Caruso N, Quitadamo M, et al. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP. 2003; 4:41-48. (Pubitemid 38963799)
43. Moreto M, Zaballa M, Casado I, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial [see comment]. Gastrointest Endosc. 2003; 57:1-7. (Pubitemid 36236791)
44. Sudhindran S, Bromwich E, Edwards PR, et al. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography - induced pancreatitis. Br J Surg. 2001; 88:1178-1182. (Pubitemid 34015599)
45. Kaffes AJ, Bourke MJ, Ding S, et al. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc. 2006; 64:351-357. (Pubitemid 44233561)
46. Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 1999; 49:593-598. (Pubitemid 29227021)
47. Bordas JM, Toledo-Pimentel V, Llach J, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 1998; 47:230-234. (Pubitemid 28155343)
48. Guelrud M, Mendoza S, Viera L, et al. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc. 1991; 37:44-47.
49. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 2004; 19:278-282. (Pubitemid 38338736)
50. Testoni PA, Lella F, Bagnolo F, et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas. 1996; 13:61-65. (Pubitemid 26187771)
51. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther. 2001; 15:965-972. (Pubitemid 32578968)
52. Testoni PA, Lella F, Bagnolo F, et al. Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy. Ital J Gastroenterol. 1994; 26:431-436.
53. Arcidiacono R, Gambitta P, Rossi A, et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994; 26:715-718.
54. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, et al. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology. 1998; 45:248-252. (Pubitemid 28067562)
55. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992; 87:1561-1566.
56. Tulassay Z, Dobronte Z, Pronai L, et al. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther. 1998; 12:1109-1112. (Pubitemid 28508724)
57. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000; 51:1-7. (Pubitemid 30051601)
58. Binmoeller KF, Harris AG, Dumas R, et al. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut. 1992; 33:1129-1133.
59. Testoni PA, Mariani A, Masci E, et al. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis. 2006; 38:588-595. (Pubitemid 44356251)